Figure 4.

Immunization of mice with rOVA-FLIPr induces CD8⁺ T cell-mediated antitumor immunity. Groups of C57BL/6 mice (n = 6/group) were immunized twice with 30 μg of rOVA or rOVA-FLIPr at a 2-week interval. Mice immunized with PBS were used as controls. One week after the last immunization, mice were implanted with EG7 cells (5 × 10⁵). (A) Tumor growth was monitored. The results are one of two representative experiments. (B) One day before tumor implantation, mice were intraperitoneally injected with anti-CD4 antibodies, anti-CD8 antibodies, or their isotype control antibodies. Mice immunized with PBS and depleted with PBS were used as controls. Tumor growth was monitored after depletion. (C) Mice were inoculated EG7 cells (5 × 10⁴) on day 0 and immunized with 30 μg of rOVA or rOVA-FLIPr on day 3 and day 10. Mice immunized with PBS were used as controls. Tumor growth was monitored. The results are one of two representative experiments.